NCT04729621COMPLETEDanonymous

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Sponsor

Source record

Teva Pharmaceuticals USA

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

TVB-009, Prolia®

Indication / condition

AI-normalized

Osteoporosis, Postmenopausal

Intervention

Source record

TVB-009, Prolia®

Related intelligence directories

Indication directory: Osteoporosis Modality directory: monoclonal antibody Target directory: TVB-009

Source & freshness

Source record

NCT ID

NCT04729621

Original source

ClinicalTrials.gov

Source last updated

Apr 18, 2024

Ingested at

Jun 04, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04729621

Title

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Sponsor

Teva Pharmaceuticals USA

Status

COMPLETED

Phase

PHASE3

Condition raw

Osteoporosis, Postmenopausal

Condition normalized

Osteoporosis, Postmenopausal

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

TVB-009, Prolia®

Target normalized

TVB-009, Prolia®

Interventions

TVB-009, Prolia®

Public preview

Source record

Teva Pharmaceuticals USA conducted a Phase 3 clinical trial (NCT04729621) to evaluate the efficacy and safety of TVB-009P compared to Denosumab (Prolia®) in treating postmenopausal osteoporosis. The study involved 332 participants and was completed in June 2023.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT04729621

Status

COMPLETED

Phase

PHASE3

Sponsor

Teva Pharmaceuticals USA

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedApr 18, 2024

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04729621

Indication

Osteoporosis, Postmenopausal

Modality

monoclonal antibody

Target

TVB-009, Prolia®

Intervention

TVB-009, Prolia®

Source record